CoChat

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

Open access
Zak, Jaroslav, Pratumchai, Isaraphorn, Marro, Brett S., Marquardt, Kristi L., Zavareh, Reza Beheshti, Lairson, Luke L., Oldstone, Michael B. A., Varner, Judith A., Hegerova, Livia, Cao, Qing, Farooq, Umar, Kenkre, Vaishalee P., Bachanova, Veronika, Teijaro, John R. · 2024 · Science
Cited by 193

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Abstract

Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti–PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of immune checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.ade8520

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Cited by

See all 193

Metadata

Authors
Zak, J., Pratumchai, I., Marro, B. S., Marquardt, K. L., Zavareh, R. B., Lairson, L. L., Oldstone, M. B. A., Varner, J. A., Hegerova, L., Cao, Q., Farooq, U., Kenkre, V. P., Bachanova, V., & Teijaro, J. R.
Venue
Science
Published
2024-06-21
Volume
384
Issue
6702
Pages
eade8520-eade8520
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W4399848851
Cited by
193
References
88
FWCI
29.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. https://app.cochat.ai/papers/10.1126/science.ade8520
The paper
Zak, J., Pratumchai, I., Marro, B. S., Marquardt, K. L., Zavareh, R. B., Lairson, L. L., Oldstone, M. B. A., Varner, J. A., Hegerova, L., Cao, Q., Farooq, U., Kenkre, V. P., Bachanova, V., & Teijaro, J. R. (2024). JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. https://doi.org/10.1126/science.ade8520

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.